

Personalised Cancer Medicine Flashcards 2022

Ovarian Cancer



Standard

BRCA1 and BRCA2*
Homologous Recombination
Deficiency (HRD)

*germ-line or somatic

Recommended

NGS**

**approved in US as companion diagnostics for some PPAR inhibitors

Currently not recommended

p53, PD-1/PDL-1, ATM, BARD1,
BRIP1, CHECK1,
CHECK2, FAM175A, MRE11A, NBN,
PALB2, RAD51C, RAR51D.

The **Standard** category is based on current treatment indications with approved funding by the Spanish National Health System
The **Recommended** category is based on current recommendations by EMEA and FDA

1. Oaknin A, Guarch R, Barretina P, et al. Recommendations for biomarker testing in epithelial ovarian cancer: a National Consensus Statement by the Spanish Society of Pathology and the Spanish Society of Medical Oncology. Clin Transl Oncol. 2018 Mar;20(3):274-285. doi: 10.1007/s12094-017-1719-x.